What is NAPIGEN?
Founded in 2016 by a distinguished team of industry veterans and academic experts, including Dr. Hajime Sakai and Dr. Jay Keasling, NAPIGEN operates at the intersection of advanced genetics and agricultural productivity. The company specializes in developing innovative solutions designed to enhance crop performance and resilience, effectively bridging the gap between laboratory-based discovery and field-ready agricultural applications. By focusing on high-impact R&D, NAPIGEN has established itself as a key player in the effort to modernize agricultural practices, aiming to improve yields while minimizing environmental footprints. Its market position is bolstered by a leadership team with deep expertise in DuPont Pioneer research and academic excellence, providing a strong foundation for long-term technological disruption in the food supply chain.
How much funding has NAPIGEN raised?
NAPIGEN has raised a total of $7.9M across 2 funding rounds:
Debt
$72K
Angel/Seed
$7.8M
Debt (2021): $72K with participation from PPP
Angel/Seed (2022): $7.9M led by Breakout Labs, RA Capital Management, SVG Partners, and The Grantham Foundation
Key Investors in NAPIGEN
Breakout Labs
Breakout Ventures is an investment firm focused on early-stage companies that are developing research-based solutions to enhance human health and promote sustainability. They support entrepreneurs in the fields of biology, chemistry, and technology, helping them achieve critical milestones to build value.
SVG Partners
THRIVE Agrifood is a Venture and Innovation Platform focused on advancing the food and agriculture industries. They collaborate with corporations, startups, universities, and growers to address significant challenges in these sectors.
The Grantham Foundation
The Grantham Foundation is a private foundation focused on addressing climate change, which it identifies as the greatest challenge humanity faces. It aims to promote sustainable practices and technologies, advocating for a transition away from fossil fuels.
What's next for NAPIGEN?
Looking ahead, the strategic deployment of the $7.9M will likely focus on expanding the company's intellectual property portfolio and accelerating the development of its core genetic platforms. As NAPIGEN moves deeper into its growth trajectory, the focus will shift toward scaling its R&D infrastructure and fostering partnerships with global agricultural stakeholders. The company is expected to prioritize the validation of its technologies in diverse environmental conditions, ensuring that its solutions are both scalable and commercially viable. With the continued support of its investor base, NAPIGEN is poised to play a pivotal role in the transition toward more sustainable and climate-resilient agricultural systems, potentially setting new benchmarks for efficiency in the global food market.
See full NAPIGEN company page
